Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
Although atezolizumab-bevacizumab has been positioned as the standard first-line therapy in
unresectable heptocellular carcinoma, eventually most patients progressed on this regimen.
Despite of multiple drugs are approved for the management of unresectable hepatocellular
carcinoma, only a few trials have been conducted to investigate their efficacy in the
second-line setting after the progression on atezolizumab-bevacizumab. Lenvatinib is approved
first-line multikinase inhibitor in unresectable hepatocellular carcinoma, but has not yet
been investigated as second-line therapy in prospective study. In this single arm phase 2
study, the efficacy and safety of lenvatinib will be investigated for patients who progressed
on first-line atezolizumab-bevacizumab.
Phase:
Phase 2
Details
Lead Sponsor:
Asan Medical Center
Collaborators:
Bucheon St. Mary's Hospital Bundang CHA Hospital Chonnam National University Hospital Chosun University Hospital Chungbuk National University Hospital Chungnam National University Hospital Dong-A University Hospital Eisai Inc. Ewha Womans University Gachon University Gil Medical Center Gangneung Asan Hospital Gyeongsang National University Hospital Hanyang University Seoul Hospital Saint Vincent's Hospital, Korea Seoul National University Seoul National University Bundang Hospital Severance Hospital The Catholic University of Korea Ulsan University Hospital Yonsei University